|
Beta-Blocker Heart Attack Trial (BHAT) Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Beta-Blocker Heart Attack Trial (BHAT) conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Beta-Blocker Heart Attack Trial (BHAT) Clinical research trials and Beta-Blocker Heart Attack Trial (BHAT) health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Beta-Blocker Heart Attack Trial (BHAT). Beta-Blocker Heart Attack Trial (BHAT) Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Beta-Blocker Heart Attack Trial (BHAT) clinical trial. Test subjects typically receive the most expert healthcare available for their Beta-Blocker Heart Attack Trial (BHAT) condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Beta-Blocker Heart Attack Trial (BHAT)  Beta-Blocker Heart Attack Trial (BHAT)
Beta-Blocker Heart Attack Trial (BHAT)
For Condition: Arrhythmia,Cardiovascular Diseases,Coronary Disease,Death, Sudden, Cardiac,Heart Diseases,Myocardial Infarction,Myocardial Ischemia,Ventricular Fibrillation
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine whether the regular administration of the beta-blocker drug propranolol to people who had had at least one documented myocardial infarction would result in a significant reduction of mortality from all causes over the follow-up period. Eligible volunteer patients were recruited to participate in a double-blind clinical trial within 21 days after the onset of the acute event. One-half of the patients were randomly assigned to a beta-blocking drug (propranolol) and one-half to a placebo. The trial also evaluated the effect of propranolol on incidences of coronary heart disease mortality, sudden cardiac death, and nonfatal myocardial infarction plus coronary heart disease mortality in persons with documented previous myocardial infarction.
Details: BACKGROUND: Survivors of a documented myocardial infarction are recognized as having a high risk of dying relative to the general population. Serious arrhythmias, occurring with or without evidence of new infarction, are a common cause of death in this population. Theoretically, an agent which (1) can block the sympathetic nervous activity thought to be involved in precipitating sudden death and (2) has non-neurogenic antiarrhythmic properties would be of value to people with coronary heart disease. Propranolol, like other beta- blocking agents, has these as well as other properties and therefore might be expected to prevent or retard complications of coronary heart disease such as serious arrhythmias. This would be reflected in a decrease in mortality due to coronary heart disease. A workshop on chronic antiarrhythmic therapy reviewed contemporary experimental data and clinical practice and recommended that a clinical trial be undertaken to clearly show the effects of beta-blocking drugs on mortality. Subsequently, such a trial was approved by the Clinical Applications and Prevention Advisory Committee, by the Cardiology Advisory Committee, and by the National Heart, Lung, and Blood Advisory Council. The study protocol was reviewed in February 1978 and recommended for approval by the policy-data monitoring board and ad hoc members. The protocol was approved by the Director of NHLBI in March 1978. Recruitment started on June 19, 1978, and ended in October 1980. A total of 3,837 patients were randomized. Units which participated in the trial included 32 clinical centers, an EKG center, a central laboratory, a coordinating center, a 1-hour ambulatory ECG center, a 24-hour ambulatory EKG center, and an EKG tape quality control center. DESIGN NARRATIVE: A randomized, double-blind design with single experimental and control groups. Patients were recruited while in the hospital for an acute myocardial infarction and were enrolled in the study before discharge. Eligible patients fulfilled the study definition of an acute myocardial infarction. The diagnosis was based either on electrocardiographic records showing evolving QRS segment changes or on ST segment and T wave changes together with enzyme changes and appropriate clinical history. One-half of the patients were placed on therapy using a beta-blocking drug (propranolol). The other half received a placebo. The prescribed maintenance dosage of propranolol was either l80 or 240 mgs/day, depending upon serum drug levels. Intervention duration averaged 25 months.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 30 Years/69 Years
Genders: Both
Protocol Entry Criteria: Men and women, ages 30 to 69. Documented myocardial infarction.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AllanBarker, , Salt Lake Clinic Research Foundation
Additional Information:
Study ID Numbers: 11;
Study Start Date: September 1977
Record last reviewed: October 1981
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000492
Other Myocardial Ischemia Studies:
1. Observational Aspirin Use and CVD in the Physicians' Health Study
2. Honolulu Heart Program
3. Hypertension in Black Americans: A Life Course Approach
4. Pawtucket Heart Health Program
5. Chronic Stress as a Risk Factor in the Etiology of Coronary Heart Disease
Related Studies:
Other Myocardial Ischemia Clinical Trials
Other Clinical Trials
Other Clinical Trials
Beta-Blocker Heart Attack Trial (BHAT)
|
|
|
|
|
|
|
|
